RE:RE:RE:Could the volume here get any lower??????? The GOBLET trial is for four different types of gastro-intestinal cancer, including pancreatic cancer. The trial design envisions a total of 55 total patients for all four GI cancers, of which 12 were supposed to be for pancreatic cancer. We don't know how many patients have so far been enrolled in the pancreatic arm or when they were enrolled.
The GOBLET trial was expected to run from 2022 to 2027. Given that almost 1/2 of the total 55 patients were already enrolled by the end of October this is "suggestive" of encouraging results. I would expect that at least 6 patients have been enrolled in the pancreatic arm, but likely more based on the need for effective pancreatic therapy and the likelihood that the positive initial results encouraged doctors to recommend this clinical trial arm and patients to want to be part of it. But hey, I'm only guessing. Hopefully the next few weeks bring more clarity.